Bill
Bill > A07245
NY A07245
NY A07245Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, shall be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value from another company asserting patent infringement and if the nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of the no
summary
Introduced
04/29/2021
04/29/2021
In Committee
01/05/2022
01/05/2022
Crossed Over
Passed
Dead
12/31/2022
12/31/2022
Introduced Session
2021-2022 General Assembly
Bill Summary
Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, shall be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value from another company asserting patent infringement and if the nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of the nonreference drug filer's product for any period of time.
AI Summary
This bill aims to preserve access to affordable drugs by establishing a presumption that certain patent settlement agreements between brand-name and generic drug manufacturers are anticompetitive and therefore illegal. Specifically, the bill states that such an agreement will be presumed anticompetitive if the generic drug manufacturer receives anything of value from the brand-name company and agrees to limit or forgo research, development, manufacturing, marketing, or sales of its product. The bill provides exceptions if the parties can show the agreement generated procompetitive benefits or the value received by the generic was fair compensation for other goods or services. The bill also establishes penalties for violations, including civil fines of up to three times the value received or $20 million.
Committee Categories
Health and Social Services
Sponsors (40)
Richard Gottfried (D)*,
Thomas Abinanti (D),
Brian Barnwell (D),
Charles Barron (D),
Rodneyse Bichotte Hermelyn (D),
Chris Burdick (D),
Maritza Davila (D),
Jeffrey Dinowitz (D),
Steven Englebright (D),
Harvey Epstein (D),
Nathalia Ferna´ndez (D),
Mathylde Frontus (D),
Sandy Galef (D),
Deborah Glick (D),
Jessica González-Rojas (D),
Judy Griffin (D),
Aileen Gunther (D),
Andrew Hevesi (D),
Chantel Jackson (D),
Kimberly Jean-Pierre (D),
Charles Lavine (D),
Donna Lupardo (D),
Zohran Mamdani (D),
John McDonald (D),
Yuh-Line Niou (D),
Amy Paulin (D),
N. Nick Perry (D),
Dan Quart (D),
Karines Reyes (D),
Jonathan Rivera (D),
Linda Rosenthal (D),
Gina Sillitti (D),
Jo Anne Simon (D),
Doug Smith (R),
Michaelle Solages (D),
Phara Souffrant Forrest (D),
Phil Steck (D),
Al Stirpe (D),
Fred Thiele (D),
Monica Wallace (D),
Last Action
print number 7245a (on 05/23/2022)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
Loading...